β-Cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment

Diabetes Care

Volumn 37, Issue 6, 2014, Pages 1751-1758

  Halban, Philippe A ^a   Polonsky, Kenneth S ^b   Bowden, Donald W ^c   Hawkins, Meredith A ^d   Ling, Charlotte ^e   Mather, Kieren J ^f   Powers, Alvin C ^g   Rhodes, Christopher J ^h   Sussel, Lori ⁱ   Weir, Gordon C ^j  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF CHICAGO   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e LUND UNIVERSITY   (Sweden)

^f INDIANA UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Kovler Diabetes Center Department of Medicine University of Chicago ^*  (United States)

ⁱ NewYork Presbyterian Hospital   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; PIOGLITAZONE; TROGLITAZONE;

ALTERNATIVE RNA SPLICING; AMYLOID PLAQUE; ARTICLE; CELL COMMUNICATION; CELL DAMAGE; CELL LOSS; CELL PROLIFERATION; DNA METHYLATION; ENDOPLASMIC RETICULUM STRESS; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HISTONE MODIFICATION; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; METABOLIC REGULATION; METABOLIC STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; ROUX Y ANASTOMOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; DIABETES MELLITUS, TYPE 2; EXPERT WITNESS; ORGANIZATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CONGRESSES AS TOPIC; DIABETES MELLITUS, TYPE 2; EXPERT TESTIMONY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN-SECRETING CELLS; SIGNAL TRANSDUCTION;

EID: 84901445280     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0396     Document Type: Article

References (86)

1. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000;49:2201-2207
2. Ellard S, Flanagan SE, Girard CA, et al. Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet 2007;81:375-382
3. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATPsensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-1849
4. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000;17:543-545
5. Babenko AP, Polak M, Cav'e H, et al. Activating mutations in the ABCC8 gene in neonataldiabetes mellitus. N Engl J Med 2006;355:456-466 (Pubitemid 44162273
6. Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-477
7. Pal A, McCarthy MI. The genetics of type 2 diabetes and its clinical relevance. Clin Genet 2013;83:297-306
8. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC Investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579-589
9. Rosengren AH, Braun M, Mahdi T, et al. Reduced insulin exocytosis in human pancreatic b-cells with gene variants linked to type 2 diabetes.diabetes 2012;61:1726-1733
10. Flannick J, Thorleifsson G, Beer NL, et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet 2014;46: 357-363
11. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461:747-753
12. Albrechtsen A, Grarup N, Li Y, et al.; D.E.S.I.R. Study Group; DIAGRAM Consortium. Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. Diabetologia 2013;56:298-310
13. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988-1992
14. Drong AW, Lindgren CM, McCarthy MI. The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 2012;92:707-715
15. Thompson RF, Fazzari MJ, Niu H, Barzilai N, Simmons RA, Greally JM. Experimental intrauterine growth restriction induces alterations in DNA methylation and gene expression in pancreatic islets of rats. J Biol Chem 2010;285: 15111-15118
16. Park JH, Stoffers DA, Nicholls RD, Simmons RA. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest 2008;118:2316-2324
17. Sandovici I, Smith NH, Nitert MD, et al. Maternal diet and aging alter the epigenetic control of a promoter-enhancer interaction at the Hnf4a gene in rat pancreatic islets. Proc Natl Acad Sci USA 2011;108:5449-5454
18. Petry CJ, Dorling MW, Pawlak DB, Ozanne SE, Hales CN. Diabetes in old male offspring of rat dams fed a reduced protein diet. Int J Expdiabetes Res 2001;2:139-143
19. Bhandare R, Schug J, Le Lay J, et al. Genome-wide analysis of histone modifications in human pancreatic islets. Genome Res 2010; 20:428-433
20. Stitzel ML, Sethupathy P, Pearson DS, et al.; NISC Comparative Sequencing Program. Global epigenomic analysis of primary human pancreatic islets provides insights into type 2 diabetes susceptibility loci. Cell Metab 2010;12:443-455
21. Dayeh T, Volkov P, Salo S, et al. Genomewide DNA methylation analysis of human pancreatic islets from type 2 diabetic and nondiabetic donors identifies candidate genes that influence insulin secretion. PLoS Genet 2014;10: e1004160
22. Yang BT, Dayeh TA, Volkov PA, et al. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. Mol Endocrinol 2012;26:1203-1212
23. Yang BT, Dayeh TA, Kirkpatrick CL, et al. Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets. Diabetologia 2011;54:360-367
24. Ling C, Del Guerra S, Lupi R, et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008;51:615-622
25. Volkmar M, Dedeurwaerder S, Cunha DA, et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J 2012;31:1405-1426
26. Dayeh TA, Olsson AH, Volkov P, Almgren P, Ronn T, Ling C. Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets. Diabetologia 2013;56:1036-1046
27. Bramswig NC, Everett LJ, Schug J, et al. Epigenomic plasticity enables human pancreatic a to b cell reprogramming. J Clin Invest 2013; 123:1275-1284
28. Malmgren S, Sṕegel P, Danielsson AP, et al. Coordinate changes in histone modifications, mRNA levels, and metabolite profiles in clonal INS-1 832/13 b-cells accompany functional adaptations to lipotoxicity. J Biol Chem 2013; 288:11973-11987
29. Christensen DP, Dahllof M, Lundh M, et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med 2011;17:378-390
30. Guay C, Regazzi R. CirculatingmicroRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 2013;9:513-521
31. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432:226-230
32. Poy MN, Hausser J, Trajkovski M, et al. miR-375 maintains normal pancreatic alpha-and beta-cell mass. Proc Natl Acad Sci USA 2009; 106:5813-5818
33. Kameswaran V, Bramswig NC, McKenna LB, et al. Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. Cell Metab 2014;19:135-145
34. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic b cell dedifferentiation as a mechanism of diabetic b cell failure. Cell 2012;150: 1223-1234
35. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004;53(Suppl. 3): S16-S21 (Pubitemid 39564517
36. Guo S, Dai C, Guo M, et al. Inactivation of specific b cell transcription factors in type 2 diabetes. J Clin Invest 2013;123:3305-3316
37. Ferrannini E. The stunned beta cell: a brief history. Cell Metab 2010;11:349-352
38. Thorel F, N'epote V, Avril I, et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 2010;464:1149-1154
39. Schisler JC, Jensen PB, Taylor DG, et al. The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells. Proc Natl Acad Sci USA 2005;102: 7297-7302
40. Jensen MV, Haldeman JM, Zhang H, et al. Control of voltage-gated potassium channel Kv2.2 expression by pyruvate-isocitrate cycling regulates glucose-stimulated insulin secretion. J Biol Chem 2013;288:23128-23140
41. Schisler JC, Fueger PT, Babu DA, et al. Stimulation of human and rat islet beta-cell proliferation with retention of function by the homeodomain transcription factor Nkx6.1. Mol Cell Biol 2008;28:3465-3476
42. Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontes G. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010; 1801:289-298
43. Kruit JK, Wijesekara N, Fox JE, et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules.diabetes 2011;60:3186-3196
44. Montane J, Klimek-Abercrombie A, Potter KJ, Westwell-Roper C, Bruce Verchere C. Metabolic stress, IAPP and islet amyloid. Diabetes Obes Metab 2012;14(Suppl. 3):68-77
45. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nat Immunol 2010;11:897-904
46. DonathMY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
47. Donath MY. Targeting inflammation in the treatment of type 2 diabetes. Diabetes Obes Metab 2013;15(Suppl. 3):193-196
48. Ferrannini E, Natali A, Muscelli E, et al.; RISC Investigators. Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia 2011;54:1507-1516
49. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependentdiabetes mellitus. J Clin Invest 1984;74:1318-1328 (Pubitemid 15206828
50. Arslanian SA, Bacha F, Saad R, Gungor N. Family history of type 2 diabetes is associated with decreased insulin sensitivity and an impaired balance between insulin sensitivity and insulin secretion in white youth. Diabetes Care 2005;28:115-119
51. Bacha F, Gungor N, Lee S, Arslanian SA. In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes? Diabetes Care 2009; 32:100-105
52. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and b-cell function in TODAY. Diabetes Care 2013;36: 1749-1757
53. Gregg BE, Moore PC, Demozay D, et al. Formation of a human b-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab 2012;97:3197-3206
54. Meier JJ, Butler AE, Saisho Y, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 2008;57:1584-1594
55. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008;10(Suppl. 4):32-42
56. Bonner-Weir S, O'Brien TD. Islets in type 2 diabetes: in honor of Dr. Robert C. Turner. Diabetes 2008;57:2899-2904
57. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110
58. Weir GC, Bonner-Weir S. Islet b cell mass indiabetes and how it relates to function, birth, and death. Ann N Y Acad Sci 2013;1281:92-105
59. Bonner-Weir S, In't Veld PA, Weir GC. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab. 8 January 2014 [Epub ahead of print]
60. Di Gialleonardo V, de Vries EF, Di Girolamo M, Quintero AM, Dierckx RA, Signore A. Imaging of b-cell mass and insulitis in insulin-dependent (type 1) diabetes mellitus. Endocr Rev 2012;33: 892-919
61. Reiner T, Thurber G, Gaglia J, et al. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci USA 2011;108: 12815-12820
62. Clardy SM, Keliher EJ, Mohan JF, et al. Fluorescent exendin-4 derivatives for pancreatic b-cell analysis. Bioconjug Chem2013;25:171-177
63. Neutzsky-Wulff AV, Andreassen KV, Hjuler ST, et al. Future detection and monitoring ofdiabetes may entail analysis of both b-cell function and volume: how markers of b-cell loss may assist. J Transl Med 2012;10:214
64. Mari A, Pacini G. Methods for the assessment of b-cell function in vivo. In Clinical Diabetes Research: Methods and Techniques. Roden M, Ed. Hoboken, New Jersey, Wiley & Sons, 2007, p. 7-26
65. Kitabchi AE, Temprosa M, Knowler WC, et al.; Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005;54: 2404-2414
66. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF; Diabetes Prevention Program Research Group. Regression from prediabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 2009;32:1583-1588
67. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.diabetes 2013;62:3920-3926
68. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallelgroup study. Lancet 2002;359:824-830
69. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003;52:380-386
70. Foley JE, Bunck MC,Moller-Goede DL, et al. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011;54:1985-1991
71. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-5997
72. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and argininestimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008;25:152-156
73. Bunck MC, Corńer A, Eliasson B, et al. Effects of exenatide on measures of b-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34: 2041-2047
74. Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009;150:2518-2525
75. Bradley D, Conte C, Mittendorfer B, et al. Gastric bypass and banding equally improve insulin sensitivity and b cell function. J Clin Invest 2012;122:4667-4674
76. Camastra S, Gastaldelli A,Mari A, et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia 2011;54:2093-2102
77. Cummings DE. Metabolic surgery for type 2 diabetes. Nat Med 2012;18:656-658
78. Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012;35:1420-1428
79. Rhee NA, Vilsbøll T, Knop FK. Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes.diabetes Obes Metab 2012;14:291-298
80. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005;353:249-254
81. Marsk R, Jonas E, Rasmussen F, Naslund E. Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986-2006 in Sweden. Diabetologia 2010; 53:2307-2311
82. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93-102
83. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760 (Pubitemid 351697950
84. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-1526 (Pubitemid 46588416
85. Bunck MC, DiamantM, Corńer A, et al. Oneyear treatment with exenatide improves betacell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-768
86. Marselli L, Suleiman M, Masini M, et al. Are we overestimating the loss of beta cells in type 2 diabetes? Diabetologia 2014;57:362-365